Arvaya Healthcare Ltd
Incorporated in 1985, Bijoy Hans Ltd offers medical and lifestyle solutions through physical infrastructure and digital platforms.[1]
- Market Cap ₹ 493 Cr.
- Current Price ₹ 103
- High / Low ₹ 145 / 47.7
- Stock P/E 322
- Book Value ₹ 13.1
- Dividend Yield 0.00 %
- ROCE 2.62 %
- ROE 2.70 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 198 days to 123 days
Cons
- Stock is trading at 7.82 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 30.6%
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.1.40 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 0.28 | 9.11 | |
| 0.80 | 8.37 | |
| Operating Profit | -0.52 | 0.74 |
| OPM % | -185.71% | 8.12% |
| 0.75 | 1.40 | |
| Interest | 0.01 | 0.43 |
| Depreciation | 0.02 | 0.62 |
| Profit before tax | 0.20 | 1.09 |
| Tax % | 30.00% | 17.43% |
| 0.14 | 0.90 | |
| EPS in Rs | 0.47 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 3154% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 291% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| 1 Year: | 115% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 3.00 | 48.02 |
| Reserves | 0.53 | 15.05 |
| 0.00 | 49.38 | |
| 0.06 | 28.17 | |
| Total Liabilities | 3.59 | 140.62 |
| 0.00 | 92.04 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.13 | 0.16 |
| 3.46 | 48.42 | |
| Total Assets | 3.59 | 140.62 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 0.22 | -3.28 | |
| 0.92 | -5.58 | |
| -0.06 | 8.50 | |
| Net Cash Flow | 1.08 | -0.36 |
| Free Cash Flow | 1.14 | -7.94 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -48% | -443% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 0.00 | 88.14 |
| Inventory Days | 0.00 | 546.06 |
| Days Payable | 3,279.25 | |
| Cash Conversion Cycle | 0.00 | -2,645.04 |
| Working Capital Days | 273.75 | 122.60 |
| ROCE % | 2.62% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses (Headcount Proxy) Rupees ・Standalone data |
|
||||||||||
| Interest Income on Deposits Rupees ・Standalone data |
|||||||||||
| Non-Current Investments (Investment Portfolio) Rupees ・Standalone data |
|||||||||||
| Trade Receivables Rupees ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 7(2)(A) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
- Director Bidari Kotresh Anilkumar received 591,129 shares on preferential basis on 24 October 2026.
-
Announcement under Regulation 30 (LODR)-Allotment
- Board approved allotment of 38.71 lakh shares at ₹40 each, raising ₹15.49 crore via share swap.
-
Board Meeting Outcome for Outcome Of Meeting Of Board Of Arvaya Healthcare Limited (Formerly Known As Bijoy Hans Limited) Held On 24Th October 2026
- Board approved allotment of 38.72 lakh shares at ₹40 each for ₹15.49 crore share swap with SIGPL shareholders.
-
Board Meeting Intimation for To Consider And Approve The Allotment Of 38,71,854 Equity Shares Of The Company To The Shareholders Of Sushodha Institute Of Gastroenterology Private Limited ('SIGPL') On Preferential Basis For Consideration Other Than Cash.
- Board meeting on 24 Oct 2026 to consider allotting 38,71,854 shares to SIGPL shareholders.
-
Announcement under Regulation 30 (LODR)-Preferential Issue
- BSE granted in-principle approval for 38,71,854 shares at Rs. 40 each on 12 October 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
BHL is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics, and investments.